Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00556140 · ClinicalTrials.gov registry record · Phase 3
The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression
A Phase 3 study of Psychotic Depression, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00556140 is a Phase 3 study of Psychotic Depression that has completed, run by Massachusetts General Hospital. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00556140, a Phase 3 study of Psychotic Depression, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.
Conditions Studied
Interventions
- DRUG Aripiprazole
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2003-06 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00556140
The ClinicalTrials.gov registry entry for NCT00556140 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psychotic Depression appearing as the primary indexed condition, and to 1 intervention - of which Aripiprazole is the first listed.
NCT00556140 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00556140 about?
NCT00556140 is a clinical study titled "The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression". The purpose of the study is to assess the safety and effectiveness of the combination of aripiprazole (Abilify) and selective serotonin reuptake inhibitors (SSRIs) in subjects with psychotic major depression.
What is the current status of trial NCT00556140?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2003-06. Estimated completion is 2008-01.
What conditions does trial NCT00556140 study?
This clinical trial studies the following conditions: Psychotic Depression.
What interventions are being tested in trial NCT00556140?
The interventions under investigation include: Aripiprazole (DRUG).
Who is sponsoring clinical trial NCT00556140?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00556140 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.